Clinical Trial: Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07549022) titled 'Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor' on April 18.

Brief Summary: People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available medicines for people with MPNST. Methylthioadenosine Phosphorylase (MTAP) loss is a gene mutation that some people have. MTAP loss seems to increase the chance that BMS-986504 can kill MPNST cancer cells. People who are missing MTAP from their tumor may be able to enroll in this study. Treating ...